(Q39423726)

11 September 2017

title

High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder (English)

1 reference

11 September 2017

Zhe Zhang

1

1 reference

11 September 2017

Guojun Zhang

series ordinal

2

1 reference

11 September 2017

Chuize Kong

series ordinal

3

1 reference

11 September 2017

publication date

20 December 2011

1 reference

11 September 2017

1 reference

11 September 2017

volume

31

1 reference

11 September 2017

issue

7

1 reference

11 September 2017

page(s)

1222-1230

1 reference

Urothelial cancer biomarkers for detection and surveillance

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Polo-like kinases and oncogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Regulation of cell cycle checkpoints by polo-like kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Induction of antitumor immunity using dendritic cells electroporated with Polo-like kinase 1 (Plk1) mRNA in murine tumor models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras-MKK3-p38 to regulate in vitro cellular invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Progress in the discovery of polo-like kinase inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Polo-like kinase 1 may regulate G2/M transition of mouse fertilized eggs by means of inhibiting the phosphorylation of Tyr 15 of Cdc2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Regulation of the final stage of mitosis by components of the pre-replicative complex and a polo kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Polo-like kinases (Plks) and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Polo-like kinase 1 is involved in invasion through extracellular matrix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Rapid functional screening of effective siRNAs against Plk1 and its growth inhibitory effects in laryngeal carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Normal cells, but not cancer cells, survive severe Plk1 depletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.11.028

10.1016/J.UROLONC.2011.11.028

7 January 2021

Identifiers

DOI

1 reference

11 September 2017

1 reference